SAN
DIEGO, Aug. 31, 2023 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that
Dr. Helen Torley, president and
chief executive officer, is scheduled to present and host investor
meetings at the following investor conferences.
Details on the presentations are as follow:
Event:
|
|
|
|
2023 Wells Fargo
Healthcare Conference
|
Format:
|
|
|
|
Fireside Chat and 1x1
Meetings
|
Presentation
Date:
|
|
|
|
Thursday, September 7,
2023
|
Presentation
Time:
|
|
|
|
8:00 a.m. ET / 5:00
a.m. PT
|
Location:
|
|
|
|
Boston, MA
|
|
|
|
|
|
Event:
|
|
|
|
H.C. Wainwright 25th
Annual Global Investment Conference
|
Format:
|
|
|
|
Fireside Chat and 1x1
Meetings
|
Presentation
Date:
|
|
|
|
Monday, September 11,
2023
|
Presentation
Time:
|
|
|
|
9:30 a.m. ET / 6:30
a.m. PT
|
Location:
|
|
|
|
New York, NY
|
|
|
|
|
|
Event:
|
|
|
|
Morgan Stanley 21st
Annual Global Healthcare Conference
|
Format:
|
|
|
|
Fireside Chat and 1x1
Meetings
|
Presentation
Date:
|
|
|
|
Tuesday, September 12,
2023
|
Presentation
Time:
|
|
|
|
10:50 a.m. ET / 7:50
a.m. PT
|
Location:
|
|
|
|
New York, NY
|
|
|
|
|
|
Event:
|
|
|
|
Baird 2023 Global
Healthcare Conference
|
Format:
|
|
|
|
Fireside Chat and 1x1
Meetings
|
Presentation
Date:
|
|
|
|
Wednesday, September
13, 2023
|
Presentation
Time:
|
|
|
|
1:25 p.m. ET / 10:25
a.m. PT
|
Location:
|
|
|
|
New York, NY
|
|
|
|
|
|
A live audio webcast of the Wells Fargo, H.C. Wainwright and
Morgan Stanley presentations will be available in the Investor
Relations section of the Company's website. Replays of the
audio webcasts will be available for 90 days following the
conference.
About Halozyme
Halozyme is a biopharmaceutical company bringing disruptive
solutions to significantly improve patient experiences and outcomes
for emerging and established therapies. As the innovators of the
ENHANZE® technology with the proprietary enzyme rHuPH20, Halozyme's
commercially-validated solution is used to facilitate the delivery
of injected drugs and fluids in order to reduce the treatment
burden to patients. Having touched more than 700,000 patient lives
in post-marketing use in seven commercialized products across more
than 100 global markets, Halozyme has licensed its ENHANZE®
technology to leading pharmaceutical and biotechnology companies
including Roche, Takeda, Pfizer, AbbVie, Eli Lilly, Bristol Myers
Squibb, Alexion, argenx, Horizon Therapeutics, ViiV Healthcare and
Chugai Pharmaceutical. Halozyme also develops, manufactures and
commercializes, for itself or with partners, drug-device
combination products using its advanced auto-injector technology
that are designed to provide commercial or functional advantages
such as improved convenience and tolerability, and enhanced patient
comfort and adherence. The Company has a commercial portfolio of
proprietary products including XYOSTED®, TLANDO® and NOCDURNA® and
partnered commercial products and ongoing product development
programs with several pharmaceutical companies including Teva
Pharmaceuticals and Idorsia Pharmaceuticals.
Halozyme is headquartered in San
Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations
facility.
For more information visit www.halozyme.com and connect with us
on LinkedIn and Twitter.
Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@halozyme.com
Dawn Schottlandt
Argot Partners
212-600-1902
Halozyme@argotpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/halozyme-to-present-at-upcoming-investor-conferences-301914448.html
SOURCE Halozyme Therapeutics, Inc.